Patients Shed 15% of Body Weight With Tirzepatide, Drugmaker Says

(MedPage Today) -- The hotly anticipated combination GIP/GLP-1 receptor agonist tirzepatide (Mounjaro) succeeded in yet another weight-loss trial, maker Eli Lilly announced. Meeting the first co-primary endpoint of the SURMOUNT-2 trial, people...
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news